Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.25 Insider Own0.30% Shs Outstand179.29M Perf Week-5.03%
Market Cap16.20B Forward P/E438.69 EPS next Y0.21 Insider Trans-9.84% Shs Float178.75M Perf Month4.64%
Income-42.50M PEG- EPS next Q-0.09 Inst Own99.00% Short Float4.87% Perf Quarter15.11%
Sales1.60B P/S10.11 EPS this Y-1.80% Inst Trans0.37% Short Ratio6.79 Perf Half Y22.64%
Book/sh17.15 P/B5.27 EPS next Y165.50% ROA-1.00% Target Price115.70 Perf Year-3.10%
Cash/sh4.02 P/C22.48 EPS next 5Y- ROE-1.40% 52W Range62.88 - 96.20 Perf YTD6.88%
Dividend- P/FCF- EPS past 5Y19.40% ROI-1.50% 52W High-6.06% Beta1.37
Dividend %- Quick Ratio2.50 Sales past 5Y22.10% Gross Margin78.90% 52W Low43.72% ATR2.82
Employees2849 Current Ratio3.80 Sales Q/Q17.70% Oper. Margin-8.10% RSI (14)54.98 Volatility4.46% 2.77%
OptionableYes Debt/Eq0.28 EPS Q/Q516.30% Profit Margin-2.70% Rel Volume1.77 Prev Close89.82
ShortableYes LT Debt/Eq0.28 EarningsFeb 26 AMC Payout- Avg Volume1.28M Price90.37
Recom1.80 SMA201.88% SMA503.67% SMA20013.14% Volume2,271,320 Change0.61%
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
May-23-19Resumed Citigroup Buy
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Aug-07-18Reiterated Stifel Buy $109 → $114
Aug-03-18Reiterated Stifel Buy $102 → $109
May-16-18Initiated Canaccord Genuity Buy $101
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Feb-27-20 10:38AM  BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus Zacks
10:06AM  Stock Market News for Feb 27, 2020 Zacks
03:10AM  Edited Transcript of BMRN earnings conference call or presentation 26-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-26-20 05:35PM  BioMarin Pharmaceutical (BMRN) Q4 Earnings Top Estimates Zacks
05:00AM  Biomarin- Gene Therapy and Hemophilia MoneyShow
Feb-24-20 09:28AM  BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards? Zacks
08:59AM  BioMarin (BMRN) Catches Eye: Stock Jumps 6.1% Zacks
Feb-21-20 07:46AM  The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga +6.13%
Feb-20-20 04:05PM  BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 PR Newswire
06:49AM  Health-care stocks hinge on presidential politics and theyre now looking favorable MarketWatch
Feb-19-20 12:31PM  BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? Zacks
Feb-18-20 05:22PM  Frank Sands' Firm Sells 4 Stocks in 4th Quarter GuruFocus.com
Feb-12-20 08:30AM  BioMarin to Participate in Two Upcoming Investor Conferences PR Newswire
Feb-11-20 05:54PM  Drug makers tap genetic test to save kids with seizures American City Business Journals
Feb-04-20 05:29PM  Goldman Sachs Sets BioMarin Target 75% Above Current Price GuruFocus.com
07:51AM  The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares Benzinga
Feb-03-20 04:30PM  BioMarin Announces CFO Succession PR Newswire
11:27AM  Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-29-20 08:30AM  BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET PR Newswire
Jan-27-20 09:08AM  3 Biotech Stocks Nearing Support Investopedia
Jan-26-20 09:55AM  Barron's Picks And Pans: BioMarin, Caesars, Royal Caribbean And More Benzinga
Jan-24-20 03:56PM  BioMarin Stock Jumps as Analyst Calls Doubts Over Hemophilia Drug Overblown Barrons.com
Jan-15-20 10:35AM  Gene therapy company eyes adding 100 jobs at new East Bay plant American City Business Journals
10:02AM  3 Healthcare Stocks That Are Coming Back to Life TipRanks
Jan-14-20 08:33AM  BioMarin to Begin Early-Stage Study on Gene Therapy for PKU Zacks
Jan-13-20 02:30PM  'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment American City Business Journals
08:29AM  BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy PR Newswire
Jan-10-20 08:40AM  BioMarin (BMRN) Catches Eye: Stock Jumps 5.8% Zacks
Jan-08-20 08:30AM  BioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York PR Newswire
07:30AM  Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy PR Newswire
Jan-06-20 11:35AM  3 Best Stocks for 2020: The Race Is On TipRanks
08:30AM  BioMarin to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Jan-04-20 08:03AM  Investors Who Bought BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Five Years Ago Are Now Down 10% Simply Wall St.
Jan-03-20 05:43PM  2020 Preview: The year ahead in Bay Area biotech and health American City Business Journals
Jan-02-20 08:31AM  BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A PR Newswire
Dec-25-19 06:14PM  BioMarin Pharmaceutical Inc. (BMRN) vs. Hedge Fund Favorites in 2019 Insider Monkey
Dec-24-19 12:00PM  BioMarin (BMRN) Upgraded to Strong Buy: Here's Why Zacks
09:30AM  BioMarin Files BLA for Gene Therapy to Treat Hemophilia A Zacks
Dec-23-19 05:42PM  Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests American City Business Journals
08:36AM  BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A PR Newswire
08:31AM  European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A PR Newswire
Dec-16-19 09:57AM  BioMarin shares gain on positive dwarfism drug data MarketWatch
08:15AM  BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide PR Newswire
Dec-06-19 09:33AM  The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
10:12AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-03-19 12:37PM  Gene Therapy M&A Appetite Provides Lift After Audentes Deal Bloomberg
11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga
09:31AM  Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals. Barrons.com
Dec-01-19 04:28AM  Edited Transcript of BMRN earnings conference call or presentation 23-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
Nov-28-19 06:52PM  BioMarin Pharmaceutical Inc. (BMRN): Hedge Funds In Wait-and-See Mode Insider Monkey
09:30AM  REGN or BMRN: Which Is the Better Value Stock Right Now? Zacks
Nov-27-19 11:59AM  BioMarin Stock Jumps on Analyst Upgrade Barrons.com
08:24AM  The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion Zacks
Nov-26-19 06:07AM  4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal Zacks
Nov-22-19 10:29AM  BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A Zacks
10:16AM  Investors Hope for More From Takeda Than a Healthy Dividend GuruFocus.com
09:31AM  BioMarin (BMRN) Up 11% Since Last Earnings Report: Can It Continue? Zacks
Nov-21-19 04:04PM  BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A PR Newswire
Nov-20-19 06:10PM  These 3 Strong Buy Healthcare Stocks Have 40% Upside Or More, Says Cowen TipRanks
Nov-15-19 04:00AM  BioMarin Can Trade Sideways in the Near-Term, Use It as a Buying Opportunity TheStreet.com
Nov-14-19 11:01AM  Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York PR Newswire
08:27AM  BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study PR Newswire
Nov-12-19 11:37AM  Buy Big Biotech But Not Gilead, Analyst Says Barrons.com
10:32AM  The Winds Have Changed for BioMarin TheStreet.com
09:30AM  REGN or BMRN: Which Is the Better Value Stock Right Now? Zacks
08:30AM  BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019 PR Newswire
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
10:02AM  After sons rare disease diagnosis, father finds hope through film festival American City Business Journals
Nov-06-19 04:05PM  BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th PR Newswire
Oct-30-19 09:23AM  Can The Uptrend Continue for BioMarin Pharmaceutical? Zacks
Oct-29-19 09:00AM  BioMarin (BMRN) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Oct-24-19 12:50PM  BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 Zacks
10:03AM  BioMarin Stock Rises on Earnings Beat Barrons.com
09:30AM  HZNP or BMRN: Which Is the Better Value Stock Right Now? Zacks
Oct-23-19 05:55PM  BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings and Revenue Estimates Zacks
04:05PM  BioMarin Announces Third Quarter 2019 Financial Results PR Newswire
07:54AM  The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data Benzinga
Oct-22-19 11:32AM  Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More Zacks
Oct-20-19 08:08AM  The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-19-19 09:14AM  BioMarin Pharmaceutical (NASDAQ:BMRN) Is Carrying A Fair Bit Of Debt Simply Wall St.
Oct-18-19 06:23PM  BioMarin Pharmaceutical Inc. (BMRN): Hedge Funds Fumbled the Ball Insider Monkey
Oct-17-19 10:41AM  4 Biotech Stocks That Are Set to Rally, Analyst Says Barrons.com
Oct-16-19 10:33AM  BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Oct-09-19 08:31AM  BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET PR Newswire
Oct-07-19 08:31AM  BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer PR Newswire
Oct-01-19 05:10PM  It's not just Google: 'Fierce' competition for tech talent is pushing median salaries past $200K at many Silicon Valley companies American City Business Journals
01:43PM  Biotech Roundtable: How to Invest in Medicines Future Barrons.com
08:30AM  BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York PR Newswire
Sep-30-19 02:52PM  Investors flee Biotech ETFs as they Lag Bull Market Investopedia
11:00AM  Healthcare: Political Uncertainties Have Weighed on the Sector Morningstar
Sep-27-19 07:56AM  The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave Benzinga
Sep-26-19 08:31AM  BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU PR Newswire
Sep-20-19 01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
Sep-15-19 03:28PM  Stocks That Fell to 3-Year Lows in the Week of Sept. 13 GuruFocus.com
Sep-13-19 08:12AM  Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Overpaying Its CEO? Simply Wall St.
Sep-09-19 04:05PM  BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York PR Newswire
Aug-31-19 09:31AM  BioMarin (BMRN) Down 7.3% Since Last Earnings Report: Can It Rebound? Zacks
Aug-28-19 08:30AM  BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York PR Newswire
Aug-14-19 12:06PM  Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 31% Discount? Simply Wall St.
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerFeb 03Option Exercise21.5110,000215,100338,530Feb 05 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 03Sale83.5010,000835,000328,530Feb 05 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 30Option Exercise21.511,00021,510328,530Feb 03 07:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Option Exercise21.518,000172,080335,530Jan 16 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Sale87.958,000703,600327,530Jan 16 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Option Exercise21.514,00086,040331,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Sale84.924,000339,680327,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Option Exercise21.513,00064,530330,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Sale84.463,000253,380327,530Jan 09 04:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 27Option Exercise21.515,000107,550332,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 27Sale86.165,000430,800327,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Option Exercise21.513,00064,530330,530Dec 30 07:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Sale86.433,000259,290327,530Dec 30 07:27 PM
LAWLIS V BRYANDirectorDec 17Option Exercise21.513,75080,66327,340Dec 19 08:09 PM
LAWLIS V BRYANDirectorDec 17Sale83.363,750312,60023,590Dec 19 08:09 PM
Davis George EricEVP, General CounselNov 26Sale79.663,190254,11568,709Nov 27 06:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Option Exercise21.5110,000215,100337,080Nov 26 01:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 22Sale77.6010,000776,000327,080Nov 26 01:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 25Option Exercise21.515,000107,550332,520Oct 29 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 25Sale69.555,000347,750327,520Oct 29 07:16 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 27Option Exercise21.511,00021,510327,520Sep 30 08:16 PM
LAWLIS V BRYANDirectorSep 17Option Exercise21.513,75080,66327,340Sep 18 06:47 PM
LAWLIS V BRYANDirectorSep 17Sale74.473,750279,26323,590Sep 18 06:47 PM
HERON ELAINE JDirectorAug 07Option Exercise63.101,55397,99447,668Aug 08 07:34 PM
LAWLIS V BRYANDirectorJun 17Option Exercise21.513,75080,66327,340Jun 19 12:27 PM
LAWLIS V BRYANDirectorJun 17Sale81.083,750304,05023,590Jun 19 12:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Option Exercise14.3910,000143,900336,520May 14 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale82.5210,000825,193326,520May 14 07:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 09Option Exercise14.394,00057,560330,520May 13 07:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 09Sale81.974,000327,888326,520May 13 07:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Option Exercise14.394,00057,560330,520May 09 08:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 08Sale82.164,000328,625326,520May 09 08:32 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 26Option Exercise14.393,00043,170329,211Apr 30 08:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 26Sale82.883,000248,640326,211Apr 30 08:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 16Option Exercise21.511,00021,510326,211Apr 18 07:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 12Option Exercise14.394,00057,560329,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 12Sale89.124,000356,480325,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 11Option Exercise14.391,00014,390325,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 08Option Exercise14.393,00043,170327,211Apr 09 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 08Sale91.873,000275,598324,211Apr 09 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.393,00043,170327,211Apr 09 06:10 PM
Mueller BrianSVP, Corporate ControllerApr 05Sale94.002,953277,58213,660Apr 09 06:12 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Sale93.373,000280,114324,211Apr 09 06:10 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerApr 01Sale89.0013,4731,199,09747,510Apr 03 01:17 PM
LAWLIS V BRYANDirectorMar 27Option Exercise14.392,15030,93921,310Mar 29 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 27Option Exercise14.391,00014,390324,211Mar 29 06:07 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 27Sale90.001009,00060,983Mar 29 06:19 PM
LAWLIS V BRYANDirectorMar 27Sale89.762,150192,98419,160Mar 29 06:30 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 26Sale89.183,656326,02547,475Mar 27 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 25Option Exercise14.394,00057,560327,211Mar 26 07:51 PM
FUCHS HENRY JPresident, Worldwide R&DMar 25Sale87.865,932521,186124,536Mar 26 08:20 PM
Davis George EricEVP, General CounselMar 25Sale87.863,363295,47371,890Mar 26 08:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 25Sale87.864,000351,440323,211Mar 26 07:51 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 21Sale89.984,519406,63454,729Mar 25 05:18 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 19Option Exercise14.391,00014,390336,338Mar 21 05:01 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 19Sale93.073,728346,96559,248Mar 21 05:00 PM
Davis George EricEVP, General CounselMar 19Sale93.927,907742,62578,562Mar 21 05:00 PM
FUCHS HENRY JPresident, Worldwide R&DMar 18Sale94.099,597902,982136,304Mar 19 08:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise14.394,00057,560339,338Mar 19 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale94.404,000377,600335,338Mar 19 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise14.393,00043,170331,701Mar 14 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale93.423,000280,253328,701Mar 14 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Option Exercise14.394,00057,560332,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Sale91.444,000365,770328,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise14.395,00071,950333,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale88.965,000444,780328,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 07Option Exercise14.394,00057,560332,701Mar 08 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 07Sale90.784,000363,120328,701Mar 08 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DMar 04Sale95.002,196208,620142,504Mar 06 05:45 PM
open in yahoo | open in reuters | open in google